Ulcerative Colitis (UC)
Conditions
Brief summary
The exact efficacy of Zuoqing SAN enema in the treatment of Ulcerative colitis (UC) has been clinically verified. In this study, Zuoqing SAN was used to treat UC patients with large intestine damp-heat syndrome, and the traditional chinese medicine (TCM) syndrome type was large intestine damp-heat syndrome. The changes of symptoms and signs of patients before and after treatment were observed and compared, and the clinical efficacy of Zuoqing SAN in the treatment of UC large intestine damp-heat syndrome was evaluated by combining the changes of patients' symptoms, related blood indicators, improved Mayo total score, overall syndrome efficacy, clinical comprehensive efficacy and other aspects. By replicating the rat UC model, the effects of Zuoqing SAN on general survival state, colonic gross appearance and histopathological changes, related inflammatory factors, peroxisome proliferator-activated receptor γ (PPAR-γ) /nuclear factor kappa-B（NF-κB) /signal transducerand activator of transcription 1 (STAT1) pathway, macrophage M1, M2 phenotype and microangiogenesis were observed in UC rats. Thus, the specific mechanism of Zuoqing SAN in the treatment of UC was revealed. In this study, the therapeutic effect of Zuoqing Powder on UC was investigated through clinical and animal experiments, and the specific mechanism of action was studied.
Interventions
DRUGZuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
Zuoqing powder was dissolved in 100ml normal saline, retained enema, once a night
DRUGMethalazine suppository was given rectally once a day
Methalazine suppository was given rectally once a day
Sponsors
The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
① Clinically diagnosed UC; ② The severity of UC is mild to moderate. \-
Exclusion criteria
① The severity of UC is severe; ②patient with Severe liver, kidney, heart and brain diseases; ③ Patients with Chinese medicine allergy; ④ Pregnant or lactation patients. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Symptoms: frequency of stool | Follow-up for 6 months | Symptoms: frequency of stool in one day, or Daily number of bowel movements |
Contacts
Primary ContactHeng Deng, Dr.
Outcome results
None listed